跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/2023-510176-31-00
2023-510176-31-00已完成1 期

An open label, randomized, single-dose, two-sequence, two-period, crossover comparative bioavailability study to assess the pharmacokinetic and safety profile of Dofetilide intravenous solution compared to Tikosyn® (Dofetilide) oral capsule in healthy subjects under fasting conditions.

Hyloris Developments1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年7月3日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
1 期
状态
已完成
入组人数
20
试验地点
1
研究概览入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 64 years（18-64 Years）
接受健康志愿者
是

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Christophe Lyssens

Scientific

Hyloris Developments

研究点 (1)

Loading locations...

相似试验

已完成
4 期
An open label, randomized, single dose, two-sequence, two-treatment, four-period, fully replicate, cross-over pharmacokinetic study comparing Alverine citrate/Simeticone 60 mg/300 mg soft capsules to Meteospasmyl 60 mg/300 mg soft capsules in healthy male and female subjects under fed conditions.
2024-516942-21-00Zaklady Farmaceutyczne Polpharma S.A.36
已完成
4 期
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS
2023-509399-40-00Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A.30
招募中
4 期
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.
2025-521718-24-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
已完成
4 期
Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.
2024-513665-40-00Adamed Pharma S.A.62
招募中
4 期
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.
2025-522921-37-00Gebro Pharma GmbH36